# InterVenn Biosciences

> InterVenn Biosciences is a South San Francisco biotech building an AI-driven glycoproteomics platform that reads the sugar coatings on proteins to detect disease earlier. Its flagship blood test, GlycoKnow Ovarian, distinguishes ovarian cancer from benign pelvic masses with ~86% accuracy and went commercial in 2025. Founded in 2017 by Aldo Carrascoso with chemists Carolyn Bertozzi (Nobel Laureate) and Carlito Lebrilla, the company has raised roughly $244M, including a $201M Series C led by SoftBank in 2021.

- **Founded:** 2017
- **Headquarters:** South San Francisco, California, United States
- **Founders:** Aldo Carrascoso (Co-Founder & former CEO), Carolyn Bertozzi (Co-Founder, Scientific Advisor (Nobel Laureate, Chemistry 2022)), Carlito Lebrilla (Co-Founder, Scientific Advisor)
- **Team size:** ~44 employees
- **Products:** GlycoKnow Ovarian, Dawn, GlycoVision Platform
- **Notable:** Completed a $201M Series C in August 2021, led by SoftBank, Received an AMA Proprietary Laboratory Analysis (PLA) code for GlycoKnow Ovarian in 2025, Co-founded by 2022 Nobel Laureate in Chemistry Carolyn Bertozzi

## Products & services

- **GlycoKnow Ovarian** — Blood-based liquid biopsy that distinguishes ovarian cancer from benign pelvic masses with roughly 86% accuracy. Received AMA PLA code; commercially available since fall 2025.
- **Dawn** — Liquid biopsy assay for predicting patient response to immune checkpoint inhibitors in melanoma and other cancers.
- **GlycoVision Platform** — AI-driven glycoproteomics discovery platform combining liquid chromatography, mass spectrometry, and machine learning to identify glycan-based biomarkers at scale.

## Achievements

- Completed a $201M Series C in August 2021, led by SoftBank
- Received an AMA Proprietary Laboratory Analysis (PLA) code for GlycoKnow Ovarian in 2025
- Co-founded by 2022 Nobel Laureate in Chemistry Carolyn Bertozzi
- First clinically validated glycoproteomic diagnostic test in the world
- Built a platform widely described as having a near-'monopoly' on glycoproteomics at scale

## Latest updates

- **2026-02** — Partnership with Aranscia announced to accelerate national commercialization of GlycoKnow Ovarian.
- **2025-10** — GlycoKnow Ovarian becomes commercially available, aligned with PLA code effective date.
- **2025-07** — AMA issues a Proprietary Laboratory Analysis code for GlycoKnow Ovarian.
- **2021-08** — $201M Series C closed, led by SoftBank Group.

## Links

- Website: https://intervenn.com
- LinkedIn: https://www.linkedin.com/company/intervenn
- Twitter/X: https://twitter.com/vennbio
- Facebook: https://facebook.com/intervenn/

---

Profile page: https://yespress.io/intervenn-biosciences
Published by YesPress — https://yespress.io
Last updated: 2026-06-29